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Aims Renal dysfunction is associated with poor cardiovascular outcome.We investigated the relationship of kidney function
and long-term cardiovascular outcomes in patients with high risk myocardial infarction.
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Methods
and results
We studied 27 610 patients from four randomized trials of acute myocardial infarction complicated by heart
failure and/or LV dysfunction (LVEF ≤40%). Two trials excluded patients with serum creatinine ≥2.5mg/dL. Patients
were grouped by estimated glomerular filtration rate (eGFR) using the four-component Modification of Diet in
Renal Disease equation. We used adjusted Cox proportional hazard models to compare mortality and composite
cardiovascular events among eGFR groups. Median follow-up was 23months. The eGFR was approximately normally
distributed, with a mean± SD of 69.1± 20.2mL/min/1.73m2. Co-morbidities were more prevalent with lower eGFR.
The risk of death or composite outcome of cardiovascular death, myocardial infarction, stroke, or heart failure
hospitalization increased with declining eGFR. Below 75mL/min/1.73m2, each 10 unit reduction of eGFR was
associated with an adjusted hazard ratio for death of 1.13 (95% confidence interval, 1.11–1.15) and composite
cardiovascular outcome of 1.09 (95% confidence interval, 1.08–1.10). Older patients (≥75 years) with low LVEF
(<30%) had a higher incidence of mortality and adverse cardiovascular events across eGFR categories.
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Conclusions Reduced eGFR is strongly and independently associated with poor cardiovascular outcome following high risk
myocardial infarction. In these patients, the combination of older age and poor LV systolic function is associated
with increased risk of adverse events.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
The burden of kidney disease is increasing across various
populations, mainly because of ageing and the prevalence of co-
morbidities such as diabetes and hypertension.1–3 Chronic kidney
dysfunction is a risk factor for poor cardiovascular outcome.4
Population-based studies have found an increased risk of incident
myocardial infarction, cardiovascular mortality, and all-cause
mortality in subjects with chronic kidney dysfunction
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. manifested by a reduced glomerular filtration rate
(GFR).5–7
Reduced renal function appears to confer an increased risk
of mortality and adverse cardiovascular events after myocardial
infarction.8 Patients with end-stage renal disease have twice the 2-
year mortality after myocardial infarction of patients with normal
renal function.4 In large registries of all-comers with acute myocar-
dial infarction, worsening creatinine during hospitalization had a
graded association with long-term mortality.9,10 The importance
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of kidney function in patients with high risk (complicated by ven-
tricular dysfunction, and/or heart failure) myocardial infarction was
highlighted in a post-hoc analysis of the VALIANT trial11 where
reduced GFR was associated with increased risk of death and
non-fatal cardiovascular events.
Although the majority of these studies yielded consistent results,
most of them are retrospective in nature, and most included a het-
erogeneous population of patients. In addition, they included few
subjects with a low GFR and therefore failed to answer several
important related questions, such as the significance of kidney func-
tion in the lower end of the spectrum (GFR <45mL/min/1.73m2),
the differential risk of ischaemic cardiac events vs. heart failure
development with worse kidney function, and the interplay of fac-
tors such as age and LV function in the modulation of the risk
conferred by renal dysfunction.
The High-Risk Myocardial Infarction Database Initiative12
combined the databases of four large randomized trials that
enrolled patients with high risk myocardial infarction with sim-
ilar characteristics, and provides the opportunity to explore
answers to the above questions in a large prospective group of
patients. We analysed participants enrolled in the VALIANT,13
EPHESUS,14 OPTIMAAL,15 and CAPRICORN16 trials as a strat-
ified cohort of patients with high risk myocardial infarction.
This report focuses on the importance of kidney function as
a correlate for and a predictor of long-term cardiovascular
outcomes. We explore these relationships at both ends of
the GFR spectrum and examine how they may be affected by
the interaction of age and LV systolic function in this patient
population.
Methods
Patients
Patients were enrolled in one of the four trials if up to 3weeks prior
to randomization they had acute myocardial infarction complicated by
clinical and/or radiographic signs of heart failure, LV dysfunction (LVEF
≤40%), or both. Details of inclusion and exclusion criteria for each
trial have been published previously.17–20 The VALIANT and EPH-
ESUS trials excluded patients with significant renal impairment (serum
creatinine ≥2.5mg/dL). The LVEF was measured by echocardiography,
or contrast or radionuclide ventriculography. Mean follow-up duration
ranged from 16 to 32months in the four trials. The current analysis
only includes patients who had documented creatinine measurement at
baseline.
Definition of kidney disease
The National Kidney Foundation 2002 Practice Guidelines define
chronic kidney disease as the presence of kidney damage or a GFR of
<60.0mL/min/1.73m2 of body surface area for ≥3 months.10 Kidney
damage is evidenced by the presence of pathological abnormalities or
abnormal laboratory or imaging studies. Thus some patients can have
kidney damage even in the presence of a normal or mild reduction
in GFR.10 A GFR of <60mL/min/1.73m2 is considered the cut-
off value for chronic kidney disease since it indicates a significant
reduction (by more than half) compared with normal function.4 In
accordance with these guidelines, we classified patients enrolled in the ..
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.. high risk myocardial infarction trials according to their estimated GFR
(eGFR).
Estimation of the glomerular filtration
rate
The GFR is considered the most suitable variable for quantify-
ing renal function.21 To estimate the GFR (eGFR), we used the
four-component Modification of Diet in Renal Disease (MDRD)
equation,4 which incorporates age, race, sex, and serum creatinine
level:4,22
eGFR (mL/min/1.73m2) = 186 × [serum creatinine level
(mg/dL)]–1.154 × (age [years])–0.203 × (0.742 if female)× (1.21 if black).4
Characteristics and outcomes recorded
Baseline demographics, risk factors, and clinical characteristics at
the time of the myocardial infarction were recorded for each trial.
An expert Endpoint committee adjudicated all events in each of
the trials. The trials had similar definitions of various endpoints.12
The primary outcome in our analysis was death from any cause.
Secondary outcomes were death from cardiovascular causes, heart
failure hospitalization, recurrent myocardial infarction, and stroke.
Together, these formed the cardiovascular composite outcome for our
analysis.
Statistical analysis
Patients were categorized according to their eGFR at baseline. A
total of 27 610 patients had baseline creatinine values recorded. The
analysis excluded those subjects who had missing baseline eGFR
data or baseline eGFR >140 (93 patients, probably due to erro-
neous data entry). The distribution of eGFR was divided into six
categories (<30.0, 30.0–44.9, 45–59.9, 60–74.9, 75.0–124.9, and
125.0–139.9mL/min/1.73m2).
Common baseline characteristics across the four studies are pre-
sented by eGFR category. Values are reported as percentages for
categorical variables and as means with standard deviations (SDs) for
continuous variables. Cox proportional hazards models adjusted by
study were used to estimate the hazard of clinical outcomes and to
adjust for baseline covariates. Selected potential interactions were also
explored. Kaplan–Meier estimates, stratified according to the eGFR,
for death from any cause and the cardiovascular composite outcome
were determined and presented as event curves. To explore potential
interactions with age and LVEF, we examined outcomes across eGFR
categories using the cut-offs of 75 years for age and 30% for LVEF. All
P-values were two-sided, with P-values <0.05 considered statis-
tically significant. Analyses were performed using SAS software
(version 9.2).
Results
Baseline characteristics
The baseline eGFR for the 27 610 patients was approximately
normally distributed (see Supplementary material, Figure S1)
with mean± SD of 69.1± 20.2mL/min/1.73m2 (10th and 90th
percentiles of 44.1 and 95.2, respectively). Table 1 shows the
© 2013 The Authors
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Table 1 Demographics and baseline characteristics across renal function categories
Baseline characteristic Baseline eGFR categories (mL/min/1.73m2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<30,
n= 388
30–45,
n= 2616
45–60,
n= 6264
60–75,
n= 8435
75–125,
n= 9616
125–140,
n= 291
Total,
n= 27 610
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years)
Mean± SD 74.8± 8.3 73.4± 8.9 69.9± 9.5 65.1±10.5 59.6±11.0 55.4±11.3 65.1±11.4
Percentiles (25, med, 75) 70, 76, 80 68, 74, 79 64, 71, 77 58, 66, 73 52, 59, 68 47, 53, 63 57, 66, 74
Sex, n (%)
Male 113 (29) 1286 (49) 3682 (59) 6151 (73) 7916 (82) 220 (76) 19 368 (70)
Female 275 (71) 1330 (51) 2582 (41) 2284 (27) 1700 (18) 71 (24) 8242 (30)
Race, n (%)
Caucasian 373 (96) 2487 (95) 5934 (95) 7963 (94) 8881 (92) 251 (86) 25 889 (94)
Black 1 (<1) 31 (1) 74 (1) 115 (1) 248 (3) 21 (7) 490 (2)
Asian 2 (1) 24 (1) 61 (1) 84 (1) 111 (1) 0 282 (1)
Other 12 (3) 74 (3) 195 (3) 273 (3) 376 (4) 19 (7) 949 (3)
Systolic BP (mmHg)
Mean± SD 126.6± 20.4 125.1±18.6 123.7±17.7 121.4±16.4 119.5±15.9 118.9±16.5 121.7±16.9
Percentiles (25, med, 75) 110, 120, 140 110, 120, 136 110, 120, 133 110, 120, 130 110, 119, 130 108, 116, 130 110, 120, 130
Diastolic BP (mmHg)
Mean± SD 70.9± 12.9 71.7± 11.8 72.4±11.5 72.1±10.8 71.9± 10.7 72.7±11.5 72.1±11.1
Percentiles (25, med, 75) 60, 70, 80 62, 70, 80 64, 70, 80 65, 70, 80 65, 70, 80 65, 70, 80 64, 70, 80
Heart rate (b.p.m.)
Mean± SD 75.0± 12.1 76.2±13.4 75.8±13.0 75.1±12.8 76.0±12.6 77.2±13.0 75.7±12.8
Percentiles (25, med, 75) 66, 75, 82 67, 75, 84 68, 75, 84 66, 74, 82 68, 75, 84 68, 76, 85 67, 75, 83
Body mass index (kg/m2)
Mean± SD 27.4± 5.4 27.5± 4.8 27.5± 4.7 27.5± 5.0 27.6± 4.8 27.4± 5.1 27.5± 4.8
Percentiles (25, med, 75) 24, 27, 30 24, 27, 30 24, 27, 30 24, 27, 30 24, 27, 30 24, 27, 30 24, 27, 30
KILLIP class, n (%)
1 58 (15) 493 (19) 1385 (22) 2363 (28) 3089 (32) 87 (30) 7475 (27)
2 173 (45) 1336 (51) 3372 (54) 4582 (55) 5053 (53) 148 (51) 14 664(53)
3 120 (31) 590 (23) 1163 (19) 1142 (14) 1090 (11) 42 (14) 4147 (15)
4 35 (9) 188 (7) 317 (5) 314 (4) 346 (4) 13 (4) 1213 (4)
LVEF (%)
Mean± SD 33.5± 9.3 33.4± 9.2 34.0± 9.0 34.5± 8.8 34.8± 9.0 34.9± 9.1 34.4 ± 9.0
Percentiles (25, med, 75) 29, 33, 38 28, 33, 38 30, 34, 38 30, 35, 39 30, 35, 38 30, 35, 39 30, 35, 38
Column header counts are the number of subjects in each eGFR category. A total of 176 VALIANT subjects, 143 OPTIMAAL subjects, 728 CAPRICORN subjects, and 114
EPHESUS subjects who had missing baseline eGFR data or eGFR≥140 are not included in the table. Percentages (%) are calculated using subjects with non-missing data.
BP, blood pressure; eGFR, estimated glomerular filtration rate; med, median; SD, standard deviation.
distribution of the eGFR. Of these patients, 9268 (33.6%) met the
criteria for kidney disease (cut-off of eGFR<60).
The mean (± SD) age of the patients was 65.1± 11.4 years, and
70% were males. Patients with lower eGFR values were more likely
to be older and female than patients with higher eGFR. The vast
majority of the patients enrolled in the four trials were Caucasians,
with blacks constituting less than ∼2% of the overall sample.
Patients with lower eGFR had a higher systolic blood pressure at
baseline, weighed less, and were less likely to have a current or past
history of smoking than those with higher eGFR. The LVEF was not
collected in OPTIMAAL. Mean LVEF was 34.4± 9.0% in the other
three studies and was similar across the eGFR categories; however,
patients with lower eGFR had on average a more advanced Killip
class at the time of myocardial infarction in the overall population.
The prevalence of co-morbidities such as diabetes, hypertension,
history of angina, prior myocardial infarction, heart failure, and .
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.. COPD increased gradually with decreasing eGFR. Cerebrovascular
and peripheral vascular diseases were more common in patients
with renal dysfunction (Table 2).
Outcomes
During a median follow-up of 717 days (23months), 4945 patients
(18%) died and 8180 (30%) experienced the composite cardiovas-
cular outcome.
When eGFR was modelled as a continuous variable with the
hazard ratio calculated across a range of eGFR values using a
reference value of 75.0mL/min/1.73m2, the relationship between
the hazard ratio and the eGFR was curvilinear, with a steeper
increase in hazard at lower eGFR values (Figure 1). In the adjusted
model, each 10 unit decrease in the value was associated with
a hazard ratio of 1.13 [95% confidence interval (CI) 1.11–1.15,
© 2013 The Authors
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Table 2 Medical history and baseline medications across renal function categories
Disease history Baseline eGFR category (mL/min/1.73m2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<30,
n= 388
30–45,
n= 2616
45–60,
n= 6264
60–75,
n= 8435
75–125,
n= 9616
125–140,
n= 291
Total,
n= 27 610
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabetes 158 (41) 949 (36) 1785 (28) 1981 (23) 2205 (23) 93 (32) 7171 (26)
Type II 106 (27) 719 (27) 1358 (22) 1547 (18) 1707 18) 69 (24) 5506 (20)
Hypertension 301 (78) 1786 (68) 3784 (60) 4302 (51) 4551 (47) 154 (53) 14878 (54)
Previous MI 161 (41) 931 (36) 1825 (29) 2022 (24) 2150 (22) 59 (20) 7148 (26)
Atrial fibrillation 93 (24) 554 (21) 1057 (17) 1007 (12) 914 (10) 19 (7) 3644 (13)
Dyslipidaemia 197 (51) 1173 (45) 2809 (45) 4130 (49) 4735 (49) 133 (46) 13 177 (48)
Renal insufficiency 129 (33) 404 (15) 279 (4) 83 (1) 22 (<1) 0 917 (3)
Heart failure 221 (57) 1402 (54) 2730 (44) 2969 (35) 3306 (34) 111 (38) 10 739 (39)
COPD 51 (13) 248 (9) 564 (9) 663 (8) 726 (8) 23 (8) 2275 (8)
Cerebrovascular accident 59 (15) 339 (13) 633 (10) 603 (7) 537 (6) 20 (7) 2191 (8)
PVD 59 (15) 326 (12) 623 (10) 625 (7) 611 (6) 21 (7) 2265 (8)
Smoking history
Never 235 (61) 1328 (51) 2842 (45) 3013 (36) 2505 (26) 68 (23) 9991 (36)
Current 37 (9) 359 (14) 1312(21) 2595 (31) 4310 (45) 157 (54) 8770 (32)
Past 115 (30) 924 (35) 2101 (34) 2816 (33) 2793 (29) 66 (23) 8815 (32)
Baseline medication use <30,
n= 388
30–45,
n= 2614
45–60,
n= 6262
60–75,
n= 8432
75–125,
n= 9614
125–140,
n= 291
Total,
n= 27 601
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACE inhibitora 189 (56) 1221 (55) 2719 (54) 3468 (54) 4330 (54) 148 (52) 12 075 (54)
ARBa 11 (3) 41 (2) 105 (2) 90 (1) 90 (1) 4 (1) 341 (2)
Diuretic 272 (70) 1671 (64) 3371 (54) 3590 (43) 3564 (37) 117 (40) 12 585 (46)
Aldosterone antagonistb 1 (4) 4 (3) 11 (4) 5 (1) 1 (<1) 0 22 (2)
Aspirin 327 (84) 2221 (85) 5376 (86) 7336 (87) 8523 (89) 262 (90) 24 045 (87)
Antiplatelet (excluding aspirin)a 62 (18) 405 (18) 1074 (22) 1676 (26) 2658 (33) 105 (37) 5980 (27)
Vitamin K antagonist 49 (13) 285 (11) 675 (11) 862 (10) 937 (10) 35 (12) 2843 (10)
Calcium channel blocker 61 (16) 332 (13) 626 (10) 676 (8) 609 (6) 16 (5) 2320 (8)
Beta-blockerc 205 (57) 1481 (60) 3753 (63) 5347 (66) 6518 (71) 226 (79) 17 530 (66)
Statin 112 (29) 721 (28) 1979 (32) 3001 (36) 3716 (39) 116 (40) 9645 (35)
Digitalis 75 (19) 430 (16) 868 (14) 807 (10) 877 (9) 30 (10) 3087 (11)
Values are n (%).
Column header counts are the number of subjects in each baseline eGFR category. A total of 176 VALIANT subjects, 143 OPTIMAAL subjects, 728 CAPRICORN subjects,
and 114 EPHESUS subjects who had missing baseline eGFR data or eGFR ≥140 are not included in the table.
eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PVD, peripheral vascular disease.
aDenominators are all CAPRICORN, EPHESUS, and VALIANT subjects who have a baseline medication record and baseline eGFR data (n= 22 269).
bDenominators are all CAPRICORN subjects who have a baseline medication record and baseline eGFR data (n=1231).
cDenominators are all EPHESUS, OPTIMAAL, and VALIANT subjects who have a baseline medication record and baseline eGFR data (n= 26 370).
P< 0.001] for death and 1.09 (95% CI 1.08–1.10), P< 0.001) for
the composite cardiovascular outcome.
Lower eGFR was associated with higher mortality as well as
higher incidence of the various cardiovascular outcomes (Table 3).
Unadjusted Kaplan–Meier estimates of 3-year mortality increased
with decreasing eGFR (Table 4). A similar pattern of increasing
event rates with lower eGFR was seen with the composite
cardiovascular outcome and its individual components; stratified
log-rank P< 0.001 for all outcomes (see Supplementary material,
Figure S2).
There was a wide spectrum of risk across the categories of
eGFR, with early divergence of the Kaplan–Meier curves for both
death and the composite outcome (Figure 2). The risk of events
appears to be highest during the first 3months after myocardial ..
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.. infarction; however, it continued to increase throughout the dura-
tion of follow-up.
Using the group with an eGFR of 75.0–124.9mL/min/1.73m2
as the referent group yielded hazard ratios for death from any
cause and the composite endpoint that increased as the degree
of renal impairment increased (Table 4). After adjustment for
baseline characteristics in the multivariate model, the relationship
of increased hazard of death and of the composite outcome was
less pronounced but still highly statistically significant.
Potential interaction with left ventricular
ejection fraction and age
For mortality, an interaction between eGFR category and LVEF
(categorized using 30% as a cut-off) was statistically significant
© 2013 The Authors
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Table 3 Endpoints across renal function categories
Outcome Baseline eGFR categories (mL/min/1.73m2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
<30,
n= 388
30–45,
n= 2616
45–60,
n= 6264
60–75,
n= 8435
75–125,
n= 9616
125–140,
n= 291
Total,
n= 27 610
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death 184 (47) 902(34) 1444(23) 1284(15) 1105(11) 26(9) 4945(18)
Cardiovascular (CV) death 162(42) 790(30) 1251(20) 1089(13) 923(10) 23(8) 4238(15)
HF hospitalization 96(25) 596(23) 944(15) 865(10) 743(8) 17(6) 3261(12)
MI (fatal or non-fatal) 83(21) 472(18) 824(13) 852(10) 791(8) 14(5) 3036(11)
Stroke (fatal or non-fatal) 16(4) 143(5) 228(4) 271(3) 241(3) 7(2) 906(3)
Resuscitated sudden deatha 49(13) 277(11) 536(9) 545(6) 541(6) 14(5) 1962(7)
Composite endpoint
CV death, non-fatal MI, non-fatal
stroke, or HF hospitalization
227(59) 1301(50) 2259(36) 2284(27) 2055(21) 54(19) 8180(30)
Values are n (%).
Column header counts are the number of subjects in each baseline eGFR category. A total of 176 VALIANT subjects, 143 OPTIMAAL subjects, 728 CAPRICORN subjects,
and 114 EPHESUS subjects who had missing baseline eGFR data or eGFR ≥140 are not included in the table.
eGFR, estimated glomerular filtration rate; HF, heart failure; MI, myocardial infarction.
aResuscitated sudden death for EPHESUS, OPTIMAAL, and VALIANT; sudden death for CAPRICORN.
Figure 1 Unadjusted hazard ratio for death from any cause,
according to estimated glomerular filtration rate (GFR) at base-
line. The dotted lines represent the 95% confidence limits of the
estimate.
for the model adjusting for additional baseline covariates, specif-
ically in the eGFR 30–44.9mL/min/1.73m2 group. In those
patients with LVEF<30%, the hazard ratio for death in the
eGFR 30–44.9mL/min/1.73m2 group compared with patients in
the eGFR 75.0–124.9mL/min/1.73m2 group was 2.10 (95% CI
1.80–2.46) and, in the LVEF≥30% group, the hazard ratio was
1.56 (95% CI 1.32–1.85) (Table 5). Both LVEF groups showed a
graded relationship between eGFR and outcome. OPTIMAAL did
not collect LVEF; therefore, these results exclude OPTIMAAL
patients. The overall interaction between eGFR category and
LVEF was also significant for the composite outcome in a model
adjusting for other baseline covariates. The interaction can be
seen in Figure 3 and in Supplementary material, Table S1, which
show the percentage of death and the composite endpoint across
different eGFR, age, and LVEF categories. Overall, the highest
incidence occurred in patients older than 75 years whose LVEF .
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. was <30%. The lowest incidence occurred in patients younger
than 75 years whose LVEF was >30%.
Discussion
We have demonstrated that reduced eGFR in patients with high
risk acute myocardial infarction was associated with poor long-
term cardiovascular outcome. This relationship, present across the
spectrum of eGFR, showed a graded association, with more severe
reduction in eGFR values associated with the worst prognosis.
Furthermore, the finding was independent of other risk factors
traditionally known to predict or be associated with increased
incidence of adverse events.
Our findings are consistent with previous studies. We confirmed
the results of the prior VALIANT analysis11 in a larger cohort
of similar patients. The present combined analysis provides much
more precise estimates. Also, a large single-centre retrospective
study found an increased risk of in-hospital mortality even with mild
renal dysfunction.23 In a small registry study of 754 patients post-
myocardial infarction, Schiele et al. found a significant association
between decreased eGFR and higher mortality at 1 year even
after adjustment for baseline risk.24 We found that the increased
risk associated with renal dysfunction manifests early following
myocardial infarction and persists over long-term follow-up. There
was no difference in the incidence of ischaemic (stroke, myocardial
re-infarction) vs. heart failure events; the relative frequencies of
these events were similar within the different categories of renal
dysfunction (Table 3).
More recently, an analysis of patients with established vascular
disease enrolled in the BRAVO trial showed that patients with
a GFR≥125mL/min/1.73m2 were at increased risk for major
cardiovascular events.25 This phenomenon might be attributed
to an overestimation of the GFR from underlying cachexia and
decreased muscle mass causing reduced serum creatinine levels.
In contrast to the findings from the BRAVO trial, we did not find
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Figure 2 Kaplan–Meier curves for mortality (A) and the composite outcome (B) by estimated glomerular filtration rate category.
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Table 4 Hazard ratio and estimates of 3-year event rates of all-cause death and the composite endpoint associated
with different categories of estimated glomerular filtration rate
Endpoint eGFR category
(mL/min/1.73m2)
Hazard ratios from a Cox proportional
hazard model
Kaplan–Meier estimates
of 3-year mortality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI P-value Event rate 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death—unadjusted <30 5.45 4.66–6.37 0.005 55.2 48.7–61.6
30–44.9 3.52 3.23–3.85 40.9 38.5–43.3
45–59.9 2.19 2.02–2.37 26.4 25.1–27.7
60–74.9 1.38 1.27–1.49 17.9 16.9–18.9
75–124.9 1 — 13.6 12.7–14.4
125–139.9 0.76 0.52–1.12 10.3 6.4–14.2
Death—adjusteda <30 2.74 2.31–3.21 0.005
30–44.9 1.85 1.67–2.03
45–59.9 1.42 1.30–1.55
60–74.9 1.13 1.04–1.23
75–124.9 1 —
125–139.9 0.80 0.53–1.18
Death—adjustedb <30 2.79 0.27–3.42 0.004
30–44.9 1.82 1.61–2.06
45–59.9 1.48 1.34–1.64
60–74.9 1.15 1.04–1.27
75–124.9 1 —
125–139.9 0.73 0.47–1.14
Endpoint eGFR category
(mL/min/1.73m2)
Cox proportional hazard model Kaplan–Meier estimates
of 3-year mortality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI P-valuea Event rate 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Composite—unadjusted <30 3.79 3.30–4.35 0.002 65.2 59.4–71.0
30–44.9 2.9 2.70–3.11 56.4 53.9–58.8
45–59.9 1.9 1.79–2.02 40.2 38.8–41.6
60–74.9 1.32 1.24–1.40 30.6 29.5–31.8
75–124.9 1 — 24.3 23.3–25.3
125–139.9 0.85 0.65–1.12 22.6 15.2–30.1
Composite—adjusteda <30 1.97 1.70–2.28 <0.001
30–44.9 1.63 1.50–1.76
45–59.9 1.31 1.23–1.40
60–74.9 1.12 1.05–1.19
75–124.9 1 —
125–139.9 0.84 0.64–1.11
Composite—adjustedb <30 1.96 1.64–2.33 <0.001
30–44.9 1.61 1.47–1.77
45–59.9 1.34 1.24–1.45
60–74.9 1.12 1.04–1.21
75–124.9 1 —
125–139.9 0.81 0.60–1.10
Patients with an eGFR of 75–124.9mL/min/1.73m2 constitute the referent group.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
P-value is a 1 df test testing for monotone effect of eGFR category on estimated HR.
aAdjusted for: age, gender, race, systolic blood pressure, diastolic blood pressure, heart rate, body mass index, smoking history, Killip class, history of diabetes, hypertension,
angina, previous myocardial infarction, AF, dyslipidaemia, heart failure, COPD, cerebrovascular disease, peripheral vascular disease.
bAdjusted for the above, plus LV function (this excludes OPTIMAAL patients from the analysis).
that patients with an eGFR between 125 and 140mL/min/1.73m2
post-high risk myocardial infarction were at increased risk of
cardiovascular events.
Patients with decreased kidney function had increased
prevalence of co-morbidities. In general, they represent a cohort .
..
..
..
..
..
..
. of patients with multiple medical conditions and advanced disease.
In particular, diabetes and hypertension were more prevalent in
patients with lower eGFR, indicating a possible effect of the type of
renal disease (renovascular or diabetes) on outcome. Age appears
to modulate the risk conferred by worsening renal function. In the
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Table 5 Hazard ratio of death and the composite endpoint associated with different categories of estimated
glomerular filtration rate and left ventricular ejection fraction
Endpoint eGFR category mL/min/1.73m2 LVEF <30% LVEF ≥30%
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR 95% CI HR 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Death—unadjusted <30 5.52 4.27–7.14 4.55 3.44–6.00
30–44.9 3.65 3.16–4.22 2.81 2.40–3.29
45–59.9 2.18 1.92–2.48 2.03 1.76–2.33
60–74.9 1.28 1.12–1.47 1.49 1.30–1.72
75–124.9 1 — 1 —
125–139.9 0.81 0.47–1.41 0.53 0.25–1.12
Death—adjusteda <30 2.89 2.20–3.81 2.68 2.01–3.57
30–44.9 2.1 1.80–2.46 1.56 1.32–1.85
45–59.9 1.54 1.35–1.76 1.41 1.22–1.63
60–74.9 1.1 0.97–1.27 1.20 1.04–1.39
75–124.9 1 — 1 —
125–139.9 0.84 0.48–1.45 0.59 0.28–1.24
Composite—unadjusted <30 3.66 2.92–4.58 3.51 2.75–4.48
30–44.9 2.94 2.63–3.28 2.51 2.20–2.85
45–59.9 1.87 1.70–2.05 1.82 1.63–2.03
60–74.9 1.25 1.13–1.37 1.4 1.25–1.57
75–124.9 1 — 1 —
125–139.9 0.94 0.65–1.36 0.64 0.38–1.07
Composite—adjusteda <30 1.90 1.50–2.41 2.02 1.57–2.60
30–44.9 1.76 1.56–1.98 1.46 1.27–1.67
45–59.9 1.38 1.25–1.53 1.30 1.15–1.45
60–74.9 1.09 0.99–1.20 1.17 1.05–1.31
75–124.9 1 — 1 —
125–139.9 0.89 0.61–1.30 0.69 0.41–1.15
Models include eGFR category, LV function, and their interaction (this excludes OPTIMAAL patients from the analysis).
Patients with an eGFR of 75–124.9mL/min/1.73m2 constitute the referent group.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
aAdjusted for: age, gender, race, systolic blood pressure, diastolic blood pressure, heart rate, body mass index, smoking history, Killip class, history of diabetes, hypertension,
angina, previous myocardial infarction, AF, dyslipidaemia, heart failure, COPD, cerebrovascular disease, and peripheral vascular disease.
current study, older patients did have a worse renal function than
younger patients and this was associated with poor outcome. A
recent analysis of the American College of Cardiology National
Cardiovascular Data Registry showed that, in patients with acute
myocardial infarction undergoing primary PCI, the risk of in-
hospital mortality imparted by advanced renal insufficiency was
greater in those younger than 65 years of age.26 As an explanation
for this observation, severe reduction in eGFR in a younger patient
can be regarded as a manifestation of aggressive and advanced
underlying disease, as opposed to a similar reduction in an elderly
patient. We did not observe a similar finding in our study.
Patients with reduced EF following myocardial infarction are
known to have worse prognosis than those with normal EF.27,28
A single-centre prospective, observational study of patients under-
going primary PCI for acute myocardial infarction stratified patients
according to EF (>40% vs. ≤40%) and creatinine clearance by
Cockcroft–Gault formula (>60mL/min vs. ≤60mL/min). Despite
small numbers and short duration of follow-up, patients with both
impaired LV systolic and kidney function had worse outcome than
those who had either one organ dysfunction or neither.29 In the
setting of acute myocardial infarction and LV dysfunction, impaired .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. renal function can also be a manifestation of reduced kidney
perfusion as well as renal congestion, rather than secondary to
intrinsic kidney disease alone. Most patients enrolled in our study
had LV dysfunction by design (EF ≤40%). We found that lower
EF increases the risk associated with renal dysfunction. This find-
ing was strongest in the subgroup of patient with moderately
severe kidney dysfunction (eGFR 30–44.9mL/min/1.73m2). In con-
trast to patients with better or worse kidney function, the risk
in this particular group of patients appears to be modulated by
cardiac function: those patients with severe cardiac impairment
are at an even higher risk than those with less impaired LV sys-
tolic function. In patients with more advanced kidney dysfunc-
tion, and in those with normal or mildly impaired kidney func-
tion, LV function does not seem to alter the risk of events
significantly.
In the overall population, a combination of older age and
lower LVEF conferred a higher risk of mortality and adverse
cardiovascular events across eGFR categories compared with the
risk of those who were either younger and/or had better LV
function.
© 2013 The Authors
European Journal of Heart Failure © 2013 European Society of Cardiology
The impact of kidney function on outcomes following high risk MI 297
Figure 3 Death (A) and composite outcome (B) across estimated glomerular filtration rate (eGFR) categories based on age and LV function.
Strengths and limitations
This study is a stratified analysis of four large clinical trials of
patients with high risk myocardial infarction, thereby providing the
ability to analyse prospectively collected data on a large homoge-
neous cohort of patients. The independent adjudication of events
and the vast amount of data collected during the course of these
trials ensure the robustness of the findings. The large sample size
provides high statistical power, allowing for precise adjusted analy-
ses. Although the management of myocardial infarction has changed
in the past decade, with primary percutaneous revascularization
being adopted at many centres for acute myocardial infarction
with ST-segment elevation, a vast majority of the patients included
in those trials underwent revascularization when appropriate
(primary PCI or thrombolysis). The trials included patients with
and without ST-segment elevation. Nevertheless, our study has .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. some limitations. The proportion of patients in the lower eGFR
categories was small because, by design, most of these trials
excluded patients with significant renal dysfunction (creatinine
>2.5mg/dL). Therefore, the results are less robust in this patient
subgroup. We used the MDRD equation to estimate GFR, while
recognizing that this method has its inherent limitations, but per-
forms better in patients with lower GFR than other equations
(eg. Chronic Kidney Disease Epidemiology Collaboration—CKD-
EPI).30 We did not account for change in renal function over time,
which can potentially add predictive information to the baseline
one-time measurement. We did not have information on the pres-
ence of proteinuria and were not able to explore its relationship to
outcomes. We did not test for interaction with study drug because
the merged data set does not include study drug assignment of each
trial. Finally, our study population consisted mainly of Caucasians,
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with the majority being males, which limits the generalizability of
the findings to a different population.
Conclusions
In patients following myocardial infarction complicated by clinical
signs of heart failure and/or evidence of LV dysfunction, renal
dysfunction as evidenced by low eGFR is associated with worse
outcome and increased incidence of adverse cardiovascular events.
This graded relationship is true across the spectrum of kidney
function studied in these four trials. Worse kidney function is
associated with multiple co-morbidities; clinical characteristics,
such as LV systolic function and age, may modulate the increased
risk these patients.
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